GLE1
protein-codingGLE1 RNA export mediator, the group of Nucleoporins
Gene summary
This gene encodes a predicted 75-kDa polypeptide with high sequence and structure homology to yeast Gle1p, which is nuclear protein with a leucine-rich nuclear export sequence essential for poly(A)+RNA export. Inhibition of human GLE1L by microinjection of antibodies against GLE1L in HeLa cells resulted in inhibition of poly(A)+RNA export. Immunoflourescence studies show that GLE1L is localized at the nuclear pore complexes. This localization suggests that GLE1L may act at a terminal step in the export of mature RNA messages to the cytoplasm. Two alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
- GLE1L
- LCCS1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~39.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0012750
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0012750
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0009670
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0004976
Submitter: ClinGen
*GLE1* was first reported in relation to amyotrophic lateral sclerosis (ALS) in 2015 (Kaneb HM, et al., 2015, PMID: 25343993). *GLE1* regulates gene expression at multiple steps, including nuclear mRNA export, translation initiation, and translation termination. ALS-linked variants operate by altering the overall hGle1 levels and/or shifting the subcellular pools of its two isoforms, hGle1B versus hGle1A. At least 7 rare variants have been reported in relation to ALS (including splicing, missense, and nonsense variants) from 7 probands in 2 publications (PMIDs: 25343993, 34025336). Experimentally, this gene-disease relationship is supported by its function at the nuclear pore complex (PMID: 9618489) and in stress granule assembly/disassembly (PMID: 25694449), two process that have been linked to ALS. In summary, there is limited evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. Of note, *GLE1* is also Congenital arthrogryposis with anterior horn cell disease (OMIM # 611890) and Lethal congenital contracture syndrome 1 (OMIM# 253310). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in the molecular mechanism, phenotype, and inheritance pattern for ALS and thus curated it separately from the additional disease entities.
Inheritance Pattern: AD
Disease ID:MONDO:0004976
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0009670
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0009670
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0009670
Submitter: Natera
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to GLE1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001003722.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | 226 | 3 | 236 | ||
| missense | 2 | 7 | 133 | 12 | 154 | |
| nonsense | 20 | 26 | 1 | 47 | ||
| start loss | 2 | 2 | ||||
| frameshift | 37 | 30 | 67 | |||
| splice donor/acceptor (+/-2bp) | 4 | 29 | 3 | 36 | ||
| Total | 63 | 94 | 144 | 238 | 3 | 542 |
Highest pathogenic variant AF is 0.0003611135
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001003722.1 | 16 | MANE Select | |
| Ensembl | ENSP00000308622.5 | 16 | MANE Select | |
| RefSeq | NP_001397942.1 | 17 | Standard | |
| RefSeq | NP_001490.1 | 14 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| gle1 | Danio rerio | Structure: motor neuron Quality: branchiness abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- mRNA export from nucleus
- regulation of translational initiation
- regulation of translational termination
- poly(A)+ mRNA export from nucleus
Molecular Function
- inositol hexakisphosphate binding
- protein binding
- phospholipid binding
- translation initiation factor binding
- identical protein binding
Cellular Component
- extracellular space
- nuclear pore
- nucleolus
- cytoplasm
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000309971
- Coding exons
- 16
- Length
- 37589
- Individuals with no LoFs
- 125674
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 74
- Defined
- 125748
- p
- 0.000294
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.806 | 335 | 379 | 0.884 | 0.0000215 | 4568 |
| Missense (PolyPhen) | 88 | 120.45 | 0.7306 | 1437 | ||
| Synonymous | 0.835 | 128 | 141 | 0.910 | 0.00000738 | 1329 |
| Loss of Function | 2.86 | 23 | 43.3 | 0.531 | 0.00000220 | 479 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00018 | 0.00018 | rare |
| Latino/Admixed American | 0.00017 | 0.00017 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.000055 | 0.000054 | rare |
| Finnish | 0.000092 | 0.000092 | rare |
| European (Non-Finnish) | 0.00031 | 0.00031 | rare |
| South Asian | 0.00072 | 0.00072 | rare |
| Other | 0.00082 | 0.00081 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Required for the export of mRNAs containing poly(A) tails from the nucleus into the cytoplasm. May be involved in the terminal step of the mRNA transport through the nuclear pore complex (NPC). {ECO:0000269|PubMed:12668658, ECO:0000269|PubMed:16000379, ECO:0000269|PubMed:9618489}.;
- Disease
- DISEASE: Lethal congenital contracture syndrome 1 (LCCS1) [MIM:253310]: A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS1 patients manifest early fetal hydrops and akinesia, micrognathia, pulmonary hypoplasia, pterygia, and multiple joint contractures. It leads to prenatal death. {ECO:0000269|PubMed:18204449}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lethal arthrogryposis with anterior horn cell disease (LAAHD) [MIM:611890]: A disorder characterized by fetal akinesia, arthrogryposis and motor neuron loss. The fetus often survives delivery, but dies early as a result of respiratory failure. Neuropathological findings resemble those of lethal congenital contracture syndrome type 1, but are less severe. {ECO:0000269|PubMed:18204449}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.102
Intolerance Scores
- LoFtool
- 0.923
- RVIS EVS
- -0.09
- RVIS percentile EVS
- 47.06
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.647
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |